BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ison MG. Antiviral Treatments. Clin Chest Med 2017;38:139-53. [PMID: 28159156 DOI: 10.1016/j.ccm.2016.11.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Cowling BJ, Chui CSL, Lim WW, Wu P, Hui CKM, Peiris JSM, Chan EW. Use of influenza antivirals in patients hospitalized in Hong Kong, 2000-2015. PLoS One 2018;13:e0190306. [PMID: 29351330 DOI: 10.1371/journal.pone.0190306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Berry KN, Kober DL, Su A, Brett TJ. Limiting Respiratory Viral Infection by Targeting Antiviral and Immunological Functions of BST-2/Tetherin: Knowledge and Gaps. Bioessays 2018;40:e1800086. [PMID: 30113067 DOI: 10.1002/bies.201800086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Massari S, Bertagnin C, Pismataro MC, Donnadio A, Nannetti G, Felicetti T, Di Bona S, Nizi MG, Tensi L, Manfroni G, Loza MI, Sabatini S, Cecchetti V, Brea J, Goracci L, Loregian A, Tabarrini O. Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. Eur J Med Chem 2021;209:112944. [PMID: 33328103 DOI: 10.1016/j.ejmech.2020.112944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Drugs for Influenza Treatment: Is There Significant News? Front Med (Lausanne) 2019;6:109. [PMID: 31192211 DOI: 10.3389/fmed.2019.00109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
5 Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin Drug Investig 2018;38:1189-96. [PMID: 30288682 DOI: 10.1007/s40261-018-0710-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
6 Restori KH, Srinivasa BT, Ward BJ, Fixman ED. Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma. Front Immunol 2018;9:1249. [PMID: 29915592 DOI: 10.3389/fimmu.2018.01249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
7 Trindade GG, Caxito SMC, Xavier AREO, Xavier MAS, BrandÃo F. COVID-19: therapeutic approaches description and discussion. An Acad Bras Cienc 2020;92:e20200466. [PMID: 32556054 DOI: 10.1590/0001-3765202020200466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2018;31:471-80. [PMID: 30299367 DOI: 10.1097/QCO.0000000000000504] [Cited by in Crossref: 68] [Cited by in F6Publishing: 36] [Article Influence: 22.7] [Reference Citation Analysis]
9 Pismataro MC, Felicetti T, Bertagnin C, Nizi MG, Bonomini A, Barreca ML, Cecchetti V, Jochmans D, De Jonghe S, Neyts J, Loregian A, Tabarrini O, Massari S. 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. Eur J Med Chem 2021;221:113494. [PMID: 33962311 DOI: 10.1016/j.ejmech.2021.113494] [Reference Citation Analysis]
10 Tonk M, Růžek D, Vilcinskas A. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2. Viruses 2021;13:912. [PMID: 34069206 DOI: 10.3390/v13050912] [Reference Citation Analysis]
11 Wang L, Xia Z, Tang W, Sun Y, Wu Y, Kwok HF, Sun F, Cao Z. p38 activation and viral infection. Expert Rev Mol Med 2022;24. [DOI: 10.1017/erm.2021.29] [Reference Citation Analysis]
12 Garber B, Glauser J. Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020. Curr Emerg Hosp Med Rep 2020;:1-6. [PMID: 32837804 DOI: 10.1007/s40138-020-00218-1] [Reference Citation Analysis]
13 Huang W, Cheng Y, Li X, Tan M, Wei H, Zhao X, Xiao N, Dong J, Wang D. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China. J Infect Chemother 2018;24:729-33. [PMID: 29866491 DOI: 10.1016/j.jiac.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cojocaru FD, Botezat D, Gardikiotis I, Uritu CM, Dodi G, Trandafir L, Rezus C, Rezus E, Tamba BI, Mihai CT. Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. Pharmaceutics 2020;12:E171. [PMID: 32085535 DOI: 10.3390/pharmaceutics12020171] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 31.5] [Reference Citation Analysis]
15 Zhao RY. Yeast for virus research. Microb Cell 2017;4:311-30. [PMID: 29082230 DOI: 10.15698/mic2017.10.592] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
16 Matos ADR, Wunderlich K, Schloer S, Schughart K, Geffers R, Seders M, Witt M, Christersson A, Wiewrodt R, Wiebe K, Barth P, Hocke A, Hippenstiel S, Hönzke K, Dittmer U, Sutter K, Rescher U, Rodionycheva S, Matera N, Ludwig S, Brunotte L. Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities. Emerg Microbes Infect 2019;8:1763-76. [PMID: 31826721 DOI: 10.1080/22221751.2019.1698271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
17 Ivanova AE, Burgart YV, Saloutin VI, Orshanskaya YR, Zarubaev VV. β-d-Ribofuranosyl substituted polyfluoroalkylpyrazoles and their activity against the influenza virus. Mendeleev Communications 2018;28:52-4. [DOI: 10.1016/j.mencom.2018.01.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
18 Davidson S. Treating Influenza Infection, From Now and Into the Future. Front Immunol 2018;9:1946. [PMID: 30250466 DOI: 10.3389/fimmu.2018.01946] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
19 Boltz D, Peng X, Muzzio M, Dash P, Thomas PG, Margitich V. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother 2018;26:2040206618811416. [PMID: 30466301 DOI: 10.1177/2040206618811416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Behzadi MA, Leyva-Grado VH. Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. Front Microbiol 2019;10:1327. [PMID: 31275265 DOI: 10.3389/fmicb.2019.01327] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 15.7] [Reference Citation Analysis]
21 Meineke R, Rimmelzwaan GF, Elbahesh H. Influenza Virus Infections and Cellular Kinases. Viruses 2019;11:E171. [PMID: 30791550 DOI: 10.3390/v11020171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
22 Othumpangat S, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2018. pp. 345-61. [DOI: 10.1016/bs.seda.2018.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral Res 2017;146:12-20. [PMID: 28802866 DOI: 10.1016/j.antiviral.2017.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
24 Brodskaia AV, Timin AS, Gorshkov AN, Muslimov AR, Bondarenko AB, Tarakanchikova YV, Zabrodskaya YA, Baranovskaya IL, Il'inskaja EV, Sakhenberg EI, Sukhorukov GB, Vasin AV. Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. Antiviral Res 2018;158:147-60. [PMID: 30092251 DOI: 10.1016/j.antiviral.2018.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
25 Radosevic D, Sencanski M, Perovic V, Veljkovic N, Prljic J, Veljkovic V, Mantlo E, Bukreyeva N, Paessler S, Glisic S. Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. Front Cell Infect Microbiol 2019;9:67. [PMID: 30972303 DOI: 10.3389/fcimb.2019.00067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral Res 2018;157:38-46. [PMID: 29981793 DOI: 10.1016/j.antiviral.2018.07.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 15.5] [Reference Citation Analysis]
27 Jia X, Liu B, Bao L, Lv Q, Li F, Li H, An Y, Zhang X, Cao B, Wang C. Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog 2018;14:e1007428. [PMID: 30422993 DOI: 10.1371/journal.ppat.1007428] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
28 Ulomskiy EN, Ivanova AV, Gorbunov EB, Esaulkova IL, Slita AV, Sinegubova EO, Voinkov EK, Drokin RA, Butorin II, Gazizullina ER, Gerasimova EL, Zarubaev VV, Rusinov VL. Synthesis and biological evaluation of 6-nitro-1,2,4-triazoloazines containing polyphenol fragments possessing antioxidant and antiviral activity. Bioorg Med Chem Lett 2020;30:127216. [PMID: 32360104 DOI: 10.1016/j.bmcl.2020.127216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Odnovorov AI, Grebennikova TV, Pleteneva TV. Specific Influenza Therapy: Current State and Prospects (Review). Razrabotka i registraciâ lekarstvennyh sredstv 2020;9:83-91. [DOI: 10.33380/2305-2066-2020-9-1-83-91] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kurskaya O, Prokopyeva E, Bi H, Sobolev I, Murashkina T, Shestopalov A, Wei L, Sharshov K. Anti-Influenza Activity of Medicinal Material Extracts from Qinghai–Tibet Plateau. Viruses 2022;14:360. [DOI: 10.3390/v14020360] [Reference Citation Analysis]
31 Tan KS, Yan Y, Ong HH, Chow VTK, Shi L, Wang DY. Impact of Respiratory Virus Infections in Exacerbation of Acute and Chronic Rhinosinusitis. Curr Allergy Asthma Rep 2017;17:24. [PMID: 28389843 DOI: 10.1007/s11882-017-0693-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
32 Zhou L, Bao L, Wang Y, Chen M, Zhang Y, Geng Z, Zhao R, Sun J, Bao Y, Shi Y, Yao R, Guo S, Cui X. An Integrated Analysis Reveals Geniposide Extracted From Gardenia jasminoides J.Ellis Regulates Calcium Signaling Pathway Essential for Influenza A Virus Replication. Front Pharmacol 2021;12:755796. [PMID: 34867371 DOI: 10.3389/fphar.2021.755796] [Reference Citation Analysis]
33 Ginex T, Luque FJ. Searching for effective antiviral small molecules against influenza A virus: A patent review. Expert Opin Ther Pat 2021;31:53-66. [PMID: 33012213 DOI: 10.1080/13543776.2020.1831471] [Reference Citation Analysis]
34 Chernyshov VV, Yarovaya OI, Fadeev DS, Gatilov YV, Esaulkova YL, Muryleva AS, Sinegubova KO, Zarubaev VV, Salakhutdinov NF. Single-stage synthesis of heterocyclic alkaloid-like compounds from (+)-camphoric acid and their antiviral activity. Mol Divers 2020;24:61-7. [PMID: 30820742 DOI: 10.1007/s11030-019-09932-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Rennick LJ, Nambulli S, Lemon K, Olinger GY, Crossland NA, Millar EL, Duprex WP. Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats. J Gen Virol 2020;101:1056-68. [PMID: 32723429 DOI: 10.1099/jgv.0.001471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 O'Sullivan S, Torres A, Rodriguez A, Martin-Loeches I. Influenza management with new therapies. Curr Opin Pulm Med 2020;26:215-21. [PMID: 32068576 DOI: 10.1097/MCP.0000000000000667] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]